Spyre Therapeutics, Inc.
SYRE
NASDAQ·Healthcare·Biotechnology·Mkt cap $7.6B
$87.05
▼ -1.64%
P/E
-44.64
Mkt Cap
$7.6B
52-Wk Range
$14.51–$110.18
52-Week Range
$14.51 - $110.18
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 417.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Selective α4β7 integrin targeting with SPY001 lead candidate
- Multi-pathway combination therapy approach (SPY120, SPY130, SPY230)
- Experienced biotechnology team and research infrastructure in Waltham, Massachusetts
- Focused pipeline addressing significant IBD market opportunity
Bear Case
1 risk
- Very high volatility (beta 3.0). Expect 3x market swings. Position size accordingly.
Growth
Stable outlook
Advancement of SPY001 through preclinical development toward IND-enabling studies
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+18.4% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying SYRE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 4, 2026
Reported EPS of -$0.36 vs -$0.76 consensus (+52.6% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+52.6%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$90.5M
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
12 analysts · 92% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
92%
Hold
8%
Sell
0%
Median Price Target
—
Latest: Guggenheim · Aug 27, 2026
vs Industry
How SYRE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related